

Sunit Talapatra

Partner

stalapatra@foley.com

Washington, D.C.

202.295.4621



Dr. Sunit Talapatra's practice focuses on the intellectual property needs of diverse technology clients spanning pharmaceuticals, diagnostics, agriculture, food and nutrition, and medical devices. He also has a unique perspective on European companies with ties to the United States, having lived in the Netherlands and frequently returning to the continent. He is a partner in the firm's Chemical, Biotechnology & Pharmaceutical, and Private Equity & Venture Capital Practices as well as the Health Care & Life Sciences Sector.

In addition to patent counseling and prosecution matters, Sunit has argued several cases before the United States Patent Trial and Appeal Board, notably orchestrating a successful defense in the "1st-Ever" Pharma AIA Ruling (*Amneal Pharma Inc v. Supernus Pharma Inc.*). Some of his exemplary patent cases include *Chatterjee v. Tabor* (interference proceeding re DNA polymerase); *Keygene NV v. Floragenex, Inc.* (patent infringement action); and *Biota Scientific Ltd. v. Kappos* (appeal of USPTO decision re obviousness of pharmaceutical formulation).

Awards and Recognition

- Recognized in *IAM Patent 1000 – The World's Leading Patent Practitioners* (2024)

Presentations and Publications

- "General Counsel Speak: Building a Forward-Thinking IP Strategy," Foley's Annual IP Conference (October 2022)
- "Perspectives on the New Normal," Foley's Annual IP Conference (October 2021)
- "Patenting Strategies: The Counsel (Corporate and Private)," FCBA Global Outreach Series (October 2016)
- "IP Management: Getting It Right in Both Europe and the US," Innovation for Health Conference (February 2014)

- “Legal Issues Facing Health Companies in the US Market,” Health & Technology Conference (September 2013)
- “Hindsight is 20/20: Entrepreneurs Share Viewpoints on What They Wish They’d Known,” Nanotech Commercialization Conference (April 2013)
- “Intellectual Property,” Wharton Business Law Conference (February 2013)
- “Intellectual Property Life Cycle Management—Thoughts to Consider in Strategic Patent Protection,” American Chemical Society (August 2012)
- “Risk vs Value: The Impact of Nanotechnology Environmental Health Safety (EHS) on Business Decisions,” Nanotech Commercialization Conference (April 2012)
- “What’s ‘natural’ about natural resources? Implications for your IP,” American Chemical Society (March 2011)
- Talapatra S, Bent S, The Art of Negotiating with U.S. Patent Examiners, A.I.P.P.I. 56(2), (2011)
- “Negotiating a patent: the art of Examiner interviews,” American Chemical Society (August 2010)
- Talapatra S, Thompson CB, et al., Elongation Factor-1 alpha Is a Selective Regulator of Growth Factor Withdrawal and ER Stress- induced Apoptosis, Cell Death Differ., 9(8), 2002, 856-61
- Karnauskas R, Talapatra S, and Rudin C, et al., Bcl-xL and Akt Cooperate to Promote Leukemogenesis In Vivo, Oncogene, 22(5), 2003, 688-98

Thought Leadership

Sunit has authored several legal and scientific publications and is frequently quoted in *FDA Week* and *Inside Health Policy*. He also regularly lectures on patent matters, most recently at the 2016 FCBA Global Outreach Series (Paris).

Sectors

- [Racial Justice & Equity](#)

Practice Areas

- [Chemical, Biotechnology & Pharmaceutical](#)
- [Intellectual Property](#)
- [Private Equity](#)
- [Transactions](#)

Education

- The George Washington University (J.D.)
- University of Pennsylvania (Ph.D.)
 - Cell and Molecular Biology
- University of Chicago (M.S.)
 - Biochemistry
 - Molecular Biology
- University of California at Los Angeles (B.S.)

- Chemistry
- Graduate work in cancer biology was conducted under the guidance of Dr. Craig Thompson

Admissions

- Virginia
- District of Columbia
- U.S. Patent and Trademark Office